IBIO long-acting antibodies advance toward obesity and muscle milestones
IBIO is advancing long-acting antibody programs for obesity and related diseases, targeting quality and durability of weight loss. Lead programs include pathways such as Activin E and myostatin, with milestones expected in 12–18 months.